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On 4 May 2016, the evidence-based ’2016 European 
Guideline on the management of non-gonococcal ure-
thritis’ was published online [1]. This guideline is a 
comprehensive updated version of the European guide-
line from 2009 [2] and provides up-to-date and detailed 
guidance regarding aetiology, clinical features, diag-
nosis, testing, treatment and general management of 
symptomatic non-gonococcal urethritis in Europe.
The most common organisms implicated are Chlamydia 
trachomatis and Mycoplasma genitalium, with the lat-
ter perhaps causing more symptoms [3]. Testing male 
patients with urethritis for M. genitalium, preferably 
with screening for macrolide resistance, is highly likely 
to improve clinical outcomes [4]. Testing symptomatic 
patients for M. genitalium is therefore recommended.
Of major concern is the increasing azithromycin resist-
ance of M. genitalium [5]. Azithromycin, especially 
single dosage of 1 g, is associated with the develop-
ment of macrolide resistance in M. genitalium, and is 
likely to increase the circulation of macrolide-resistant 
strains in the population [5]. Consequently, single dose 
azithromycin is no longer recommended as first-line 
treatment for non-gonococcal urethritis.
Updates to the guideline include recommendations on 
the diagnosis, testing and treatment of non-gonococ-
cal urethritis:
Urethritis should be confirmed by urethral smear 
microscopy in symptomatic patients.
• Symptoms and negative urethral smear: No empiri-
cal treatment. Re-attend for early morning smear if 
nucleic acid amplification testing (NAAT) was nega-
tive and symptoms do not settle.
• All men assessed for sexually transmitted infec-
tions, regardless of symptoms, should be tested for 
C. trachomatis from a first-void urine specimen and 
for Neisseria gonorrhoeae if they have urethritis. If a 
NAAT is positive for gonorrhoea, a culture should be 
performed before treatment.
• All men who have sex with men should be tested for 
both C. trachomatis and N. gonorrhoeae from any 
potentially exposed site.
• Recommended syndromic regimen: doxycycline 
100 mg twice daily for seven days. Azithromycin 1 g 
immediately should not be used routinely because 
of the increased risk of inducing macrolide antimi-
crobial resistance with M. genitalium.
• If M. genitalium-positive: azithromycin 500 mg 
immediately, followed by a 250 mg oral dose for four 
days. A test of cure three to five weeks after treat-
ment in those who tested positive for M. genitalium 
should be performed.
In case of persistent and/or recurrent non-gonococcal 
urethritis, testing for M. genitalium using a NAAT, pref-
erably with screening for macrolide resistance, should 
be considered, as well as testing for Trichomonas vagi-
nalis using a NAAT if it is prevalent in the local popula-
tion. Recurrent non-gonococcal urethritis should only 
be treated if the patient has definite symptoms of ure-
thritis, or if there are physical signs and microscopic 
evidence of urethritis on examination.
The guidelines are available here
40 www.eurosurveillance.org
References
1. Horner PJ, Blee K, Falk L, van der Meijden W, Moi H. 2016 
European guideline on the management of non-gonococcal 
urethritis.Int J STD AIDS. 2016;2016(May):4.PMID: 27147267
2. Shahmanesh M, Moi H, Lassau F, Janier M, IUSTI/WHO. 
2009 European guideline on the management of male non-
gonococcal urethritis.Int J STD AIDS. 2009;20(7):458-64. DOI: 
10.1258/ijsa.2009.009143 PMID: 19541886
3. Falk L, Fredlund H, Jensen JS. Symptomatic urethritis is 
more prevalent in men infected with Mycoplasma genitalium 
than with Chlamydia trachomatis.Sex Transm Infect. 
2004;80(4):289-93. DOI: 10.1136/sti.2003.006817 PMID: 
15295128
4. Horner P, Blee K, Adams E. Time to manage Mycoplasma 
genitalium as an STI: but not with azithromycin 1 g!Curr 
Opin Infect Dis. 2014;27(1):68-74. DOI: 10.1097/
QCO.0000000000000030 PMID: 24322592
5. Manhart LE, Gillespie CW, Lowens MS, Khosropour CM, 
Colombara DV, Golden MR,  et al.  Standard treatment 
regimens for nongonococcal urethritis have similar but 
declining cure rates: a randomized controlled trial. Clin Infect 
Dis. 2013;56(7):934-42. DOI: 10.1093/cid/cis1022 PMID: 
23223595
License and copyright
This is an open-access article distributed under the terms of 
the Creative Commons Attribution (CC BY 4.0) Licence. You 
may share and adapt the material, but must give appropriate 
credit to the source, provide a link to the licence, and indi-
cate if changes were made.
This article is copyright of the authors, 2016.
